Trial Information

Summary: Study Assessing Gastrointestinal Symptoms Post Kidney Transplant Surgery CERL080AUS67

The purpose of this clinical research study is to determine if the FDA-approved study drug Myfortic® can replace CellCept® and be safely increased in dose, in people who have had a kidney transplant and who have had their CellCept® dose reduced due to gastrointestinal side effects. Participants must be at least 18 years and will be asked to visit the study center 4 times over a 6 and Drug Administration (FDA) for post kidney transplant treatment.

Participants will be required to visit the study center 4 times over a 6 week period.

For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: November 26, 2008 at 11:57:15 AM